Experimental Drug Helps Obese Mice Burn Fat Without Losing Muscle
An experimental small-molecule drug called 5-tetradecyloxy-2-furoic acid (TOFA) has been shown to produce an average weight loss of 18 percent in obese male mice over a four-week period without requiring the animals to eat less food or increase their physical activity, according to a study published in Science Advances. Unlike standard therapeutics that restrict appetite, the compound targets energy expenditure by slowing the production of new fat while simultaneously prompting cells to take up and burn fat for energy.
- Researchers at the University of California, Berkeley, administered TOFA orally twice daily to mice fed a high-fat diet, resulting in an 18 percent weight loss over four weeks without any alteration in food intake or physical activity.
- The treatment preserved muscle and other lean tissues while lowering blood sugar, insulin levels, and markers of fatty liver disease.
- Combining lower doses of TOFA with GLP-1-based drugs such as semaglutide produced greater weight loss outcomes by simultaneously suppressing appetite and increasing whole-body energy expenditure.
The Metabolic Mechanism of TOFA
Most contemporary pharmacological weight-loss treatments function primarily by reducing appetite and food intake. In contrast, TOFA operates by increasing the calories the body expends. According to senior author Anders Näär, a metabolic biologist at the University of California, Berkeley, speaking to ScienceAlert, whole-body energy expenditure increased by as much as 18 percent in treated animals. Food intake, physical activity, and body temperature remained unchanged.
The compound was originally made in the 1970s and has long served as a tool in laboratory research. Its ability to activate fat-burning programs remained unexamined until the UC Berkeley team investigated its therapeutic potential. The molecule appears to function through a dual mechanism: slowing the production of new fat and helping cells take up and burn fat for energy.
Physiological Improvements Beyond Weight Loss
In addition to reducing fat mass while sparing lean tissue, the administration of TOFA yielded several systemic metabolic benefits in the murine models. The treatment lowered circulating blood sugar and insulin levels, improved glucose response, and reduced lipid accumulation in the bloodstream and liver. Furthermore, the compound decreased signs associated with fatty liver disease, including hepatic fat buildup, inflammation, and scarring.
When researchers evaluated post-treatment weight maintenance, mice treated with TOFA maintained their weight for longer periods after cessation of therapy. Conversely, mice treated with semaglutide rapidly regained weight once food intake rose. These divergent trajectories underscore the distinct physiological pathways targeted by energy-expenditure agents versus appetite suppressants.
Synergistic Potential With GLP-1 Receptor Agonists
To explore complementary mechanisms, the research team administered lower doses of TOFA in combination with the GLP-1-based medications semaglutide and tirzepatide. Because GLP-1 drugs restrict energy intake while TOFA stimulates energy expenditure, the dual approach addressed both sides of the energy balance equation. The combination therapy produced greater overall weight loss and metabolic improvements compared to any single treatment arm.
Despite these promising findings, study authors noted several limitations in the current experimental design. The combination trials involved short durations and small sample sizes. Additionally, all live animal subjects in the study were male, leaving the efficacy and safety profile in females unverified. Human clinical trials have not yet been conducted, meaning the therapeutic window and potential side effect profile in patients remain unknown.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*